AIM Vaccine Co., ltd.
Manufacture Hepatitis A/B Vaccine, Rabies Vaccine (Vero cell), MPSV4 (ACYW Meningococcal Polysaccharide Vaccine), and PCV13 (Pneumococcal 13-valent conjugate vaccine)
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
RECVAX® patented adjuvant technology, through in situ adsorption technology, creates an "antigen bank" in the body after the product enters, steadily releasing antigens, extending the duration of antigen action, playing a role in enhancing the stimulation of the immune response, and improving immunogenicity. Patient vaccinated with RECVAX® 10μg have a higher positive conversion rate, higher antibody titer, longer protection time, and faster antibody production.
Immunization Rotuine and dosage
(1) Administered via intramuscular injection into the deltoid muscle of the upper arm.
(2) The immunization schedule consists of 3 doses, administered at 0, 1, and 6 months. Newborns should receive the first dose within 24 hours after birth, with one dose of vaccine administered each time.
Vaccination targets:
This vaccine is suitable for individuals susceptible to hepatitis B, especially the following people:
(1) Newborns, especially those whose mothers are positive for HBsAg and HBeAg. (2) Medical staff engaged in medical work and laboratory personnel in contact with blood.
